Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | CNR2 | P34972 | 9/20 | 0.41 |
| ▸ | CNR1 | P21554 | 6/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218634 | 0.88 | CNR2 (0.45) | PPARGCNR2CNR1MEN1ALDH1A1 | |
| SCHEMBL3218749 | 0.85 | PPARG (0.39) | PPARGCNR2CNR1MEN1ALDH1A1 | |
| SCHEMBL27716295 | 0.77 | PPARG (0.44) | PPARGCNR2CNR1 | |
| SCHEMBL3217588 | 0.77 | PPARG (0.59) | PPARGCNR2CNR1 | |
| SCHEMBL4633209 | 0.76 | PPARG (0.38) | PPARGCNR2CNR1AGERMMP2 | |
| SCHEMBL3213102 | 0.75 | CNR1 (0.38) | PPARGCNR2CNR1AGERMEN1 | |
| SCHEMBL27737202 | 0.74 | PPARG (0.43) | PPARG | |
| SCHEMBL3217512 | 0.74 | BRD4 (0.41) | CNR2CNR1MEN1ALDH1A1KMT2A | |
| SCHEMBL4601011 | 0.73 | ADRB3 (0.39) | AGERMMP2MMP3 | |
| SCHEMBL27737146 | 0.72 | PPARG (0.43) | PPARGCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885CNR2 3597/4885CNR1 3006/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885CNR2 3254/4885CNR1 2517/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885CNR2 3597/4885CNR1 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.